Does NIRAPARIB Cause Malignant neoplasm progression? 1,334 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,334 reports of Malignant neoplasm progression have been filed in association with NIRAPARIB (ZEJULA). This represents 6.2% of all adverse event reports for NIRAPARIB.
1,334
Reports of Malignant neoplasm progression with NIRAPARIB
6.2%
of all NIRAPARIB reports
62
Deaths
174
Hospitalizations
How Dangerous Is Malignant neoplasm progression From NIRAPARIB?
Of the 1,334 reports, 62 (4.6%) resulted in death, 174 (13.0%) required hospitalization, and 4 (0.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIRAPARIB. However, 1,334 reports have been filed with the FAERS database.
What Other Side Effects Does NIRAPARIB Cause?
Nausea (5,794)
Fatigue (5,240)
Constipation (4,128)
Platelet count decreased (4,102)
Insomnia (2,861)
Blood pressure increased (2,464)
Headache (2,383)
Off label use (2,213)
Vomiting (2,029)
Carbohydrate antigen 125 increased (1,868)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which NIRAPARIB Alternatives Have Lower Malignant neoplasm progression Risk?
NIRAPARIB vs NIRMATRELVIR\RITONAVIR
NIRAPARIB vs NIROGACESTAT
NIRAPARIB vs NIROGACESTAT HYDROBROMIDE
NIRAPARIB vs NIRSEVIMAB
NIRAPARIB vs NIRSEVIMAB-ALIP